Zydus Lifesciences has received approval from China’s National Medical Products Administration (NMPA) for Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg dosages. These capsules are used to treat Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). This marks the first approval Zydus has received from the NMPA in China, with production to take place at its Moraiya, Ahmedabad facility.
China Approval Received
Zydus Lifesciences has secured approval from China’s National Medical Products Administration (NMPA) for its Venlafaxine Extended-Release (ER) Capsules, available in 75 mg and 150 mg strengths. This approval, announced on November 11, 2025, represents a significant milestone for Zydus in expanding its global reach.
Therapeutic Uses
Venlafaxine ER Capsules are prescribed for the treatment of various mental health conditions, including:
- Major Depressive Disorder (MDD)
- Generalised Anxiety Disorder (GAD)
- Social Anxiety Disorder (SAD)
- Panic Disorder (PD)
These capsules function by helping to restore the balance of serotonin and norepinephrine in the brain, which can improve mood and reduce anxiety.
Manufacturing Location
The Venlafaxine ER Capsules will be manufactured at Zydus’ production facility located in Moraiya, Ahmedabad. This reflects the company’s commitment to producing high-quality medications for global markets. This is the first approval that the Group has received from NMPA in China.
Source: BSE
